151
|
Cooney GJ, Lyons RJ, Crew AJ, Jensen TE, Molero JC, Mitchell CJ, Biden TJ, Ormandy CJ, James DE, Daly RJ. Improved glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice. EMBO J 2004; 23:582-93. [PMID: 14749734 PMCID: PMC1271812 DOI: 10.1038/sj.emboj.7600082] [Citation(s) in RCA: 104] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2003] [Accepted: 12/23/2003] [Indexed: 01/10/2023] Open
Abstract
Gene targeting was used to characterize the physiological role of growth factor receptor-bound (Grb)14, an adapter-type signalling protein that associates with the insulin receptor (IR). Adult male Grb14(-/-) mice displayed improved glucose tolerance, lower circulating insulin levels, and increased incorporation of glucose into glycogen in the liver and skeletal muscle. In ex vivo studies, insulin-induced 2-deoxyglucose uptake was enhanced in soleus muscle, but not in epididymal adipose tissue. These metabolic effects correlated with tissue-specific alterations in insulin signalling. In the liver, despite lower IR autophosphorylation, enhanced insulin-induced tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and activation of protein kinase B (PKB) was observed. In skeletal muscle, IR tyrosine phosphorylation was normal, but signalling via IRS-1 and PKB was increased. Finally, no effect of Grb14 ablation was observed on insulin signalling in white adipose tissue. These findings demonstrate that Grb14 functions in vivo as a tissue-specific modulator of insulin action, most likely via repression of IR-mediated IRS-1 tyrosine phosphorylation, and highlight this protein as a potential target for therapeutic intervention.
Collapse
Affiliation(s)
- Gregory J Cooney
- Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Ruth J Lyons
- Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - A Jayne Crew
- Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Thomas E Jensen
- Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Juan Carlos Molero
- Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | | | - Trevor J Biden
- Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Christopher J Ormandy
- Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - David E James
- Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, NSW, Australia
| | - Roger J Daly
- Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, Australia
- Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria St, Sydney, NSW 2010, Australia. Tel: 61 2 92 95 8333; Fax: 61 2 92 95 8321; E-mail:
| |
Collapse
|
152
|
Kushner JA, Haj FG, Klaman LD, Dow MA, Kahn BB, Neel BG, White MF. Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. Diabetes 2004; 53:61-6. [PMID: 14693698 DOI: 10.2337/diabetes.53.1.61] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Protein tyrosine phosphatase-1b (Ptp1b) inhibits insulin and leptin signaling by dephosphorylating specific tyrosine residues in their activated receptor complexes. Insulin signals are mediated by tyrosine phosphorylation of the insulin receptor and its downstream targets, such as Irs1 and Irs2. Irs2 plays an especially important role in glucose homeostasis because it mediates some peripheral actions of insulin and promotes pancreatic beta-cell function. To determine whether the deletion of Ptp1b compensates for the absence of Irs2, we analyzed mice deficient in both Ptp1b and Irs2. Pancreatic beta-cell area decreased in Ptp1b(-/-) mice, consistent with decreased insulin requirements owing to increased peripheral insulin sensitivity. By contrast, peripheral insulin sensitivity and beta-cell area increased in Irs2(-/-)::Ptp1b(-/-) mice, which improved glucose tolerance in Irs2(-/-)::Ptp1b(-/-) mice and delayed diabetes until 3 months of age. However, beta-cell function eventually failed to compensate for absence of Irs2. Our studies demonstrate a novel role for Ptp1b in regulating beta-cell homeostasis and indicate that Ptp1b deficiency can partially compensate for lack of Irs2.
Collapse
Affiliation(s)
- Jake A Kushner
- Howard Hughes Medical Institute, Joslin Diabetes Center, and Division of Endocrinology, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | |
Collapse
|
153
|
Gum RJ, Gaede LL, Heindel MA, Waring JF, Trevillyan JM, Zinker BA, Stark ME, Wilcox D, Jirousek MR, Rondinone CM, Ulrich RG. Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice. Mol Endocrinol 2003; 17:1131-43. [PMID: 12649327 DOI: 10.1210/me.2002-0288] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Phosphorylation of stress-activated kinase p38, a MAPK family member, was increased in liver of ob/ob diabetic mice relative to lean littermates. Treatment of ob/ob mice with protein tyrosine phosphatase 1B (PTP1B) antisense oligonucleotides (ASO) reduced phosphorylation of p38 in liver-to below lean littermate levels-and normalized plasma glucose while reducing plasma insulin. Phosphorylation of ERK, but not JNK, was also decreased in ASO-treated mice. PTP1B ASO decreased TNFalpha protein levels and phosphorylation of the transcription factor cAMP response element binding protein (CREB) in liver, both of which can occur through decreased phosphorylation of p38 and both of which have been implicated in insulin resistance or hyperglycemia. Decreased p38 phosphorylation was not directly due to decreased phosphorylation of the kinases that normally phosphorylate p38-MKK3 and MKK6. Additionally, p38 phosphorylation was not enhanced in liver upon insulin stimulation of ASO-treated ob/ob mice (despite increased activation of other signaling molecules) corroborating that p38 is not directly affected via the insulin receptor. Instead, decreased phosphorylation of p38 may be due to increased expression of MAPK phosphatases, particularly the p38/ERK phosphatase PAC1 (phosphatase of activated cells). This study demonstrates that reduction of PTP1B protein using ASO reduces activation of p38 and its substrates TNFalpha and CREB in liver of diabetic mice, which correlates with decreased hyperglycemia and hyperinsulinemia.
Collapse
Affiliation(s)
- Rebecca J Gum
- Abbott Laboratories, Department R-4CK, AP10-1, 100 Abbott Park Road, Abbott Park, Illinois 60064-3502, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
154
|
Abstract
Antisense offers a precise and specific means of knocking down expression of a target gene, and is a major focus of research in neuroscience and other areas. It has application as a tool in gene function and target validation studies and is emerging as a therapeutic technology in its own right. It has become increasingly obvious, however, that there are a number of hurdles to overcome before antisense can be used effectively in the CNS, most notably finding suitable nucleic acid chemistries and an effective delivery vehicle to transport antisense oligonucleotides (AS-ODNs) across the blood-brain barrier (BBB) to their site of action. Despite these problems, a number of potential applications of AS-ODNs in CNS therapeutics have been validated in vitro and, in some cases, in vivo. Here the authors outline available nucleic acid chemistries and review progress in the development of non-invasive delivery vehicles that may be applicable to CNS therapeutics. Further to this, they discuss a number of experimental applications of AS-ODNs to CNS research and speculate on the development of antisense techniques to treat CNS disease.
Collapse
Affiliation(s)
- Jenny Godfray
- ExpressOn BioSystems Ltd, The Logan Building, Roslin BioCentre, Roslin, Midlothian EH25 9TT, Scotland.
| | | |
Collapse
|
156
|
Fletcher TM. Telomerase - strategies to exploit an important chemotherapeutic target. Expert Opin Ther Targets 2001; 5:363-378. [PMID: 12540271 DOI: 10.1517/14728222.5.3.363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Telomeres, unique protein-DNA complexes located at the chromosome ends, have important functions involving both DNA protection and cellular signalling. Telomere structure is very dynamic yet tightly controlled. One important factor is the presence of telomerase, a telomere-specific DNA polymerase activated in a majority of cancer cells. Cancer and normal cell telomeres may have dissimilar structures due to variances in telomere length, telomerase activity and levels of telomere binding proteins. In designing compounds to strictly target cancer cells, these distinctions should be investigated. Much of the recent focus has been on the development of highly effective telomerase inhibitors. Another novel group of small molecules target telomere DNA, thereby disrupting both telomerase activity and telomere structure. This class of compounds should have an immediate impact on cell growth and viability. Since many molecular characteristics of telomeres are unknown, small molecules should also be useful in probing differences in telomere dynamics unique to cancer cells.
Collapse
Affiliation(s)
- Terace M Fletcher
- National Institutes of Health, National Cancer Institute, Division of Basic Sciences, Laboratory of Receptor Biology and Gene Expression, Bethesda, MD 20892-5055, USA.
| |
Collapse
|